LLY

726.08

-2.8%↓

JNJ

153.46

-0.08%↓

ABBV

181.73

-1.73%↓

NVO

68.16

+0.29%↑

UNH

303.18

-5.79%↓

LLY

726.08

-2.8%↓

JNJ

153.46

-0.08%↓

ABBV

181.73

-1.73%↓

NVO

68.16

+0.29%↑

UNH

303.18

-5.79%↓

LLY

726.08

-2.8%↓

JNJ

153.46

-0.08%↓

ABBV

181.73

-1.73%↓

NVO

68.16

+0.29%↑

UNH

303.18

-5.79%↓

LLY

726.08

-2.8%↓

JNJ

153.46

-0.08%↓

ABBV

181.73

-1.73%↓

NVO

68.16

+0.29%↑

UNH

303.18

-5.79%↓

LLY

726.08

-2.8%↓

JNJ

153.46

-0.08%↓

ABBV

181.73

-1.73%↓

NVO

68.16

+0.29%↑

UNH

303.18

-5.79%↓

Search

REVOLUTION Medicines Inc

Open

SectorGezondheidszorg

38.61 -4.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

38.15

Max

40.68

Belangrijke statistieken

By Trading Economics

Inkomsten

-19M

-213M

EPS

-1.13

Winstmarge

-74.379

Werknemers

616

EBITDA

-24M

-237M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+75.53% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-147M

7.4B

Vorige openingsprijs

43.51

Vorige sluitingsprijs

38.61

Nieuwssentiment

By Acuity

49%

51%

176 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mei 2025, 20:54 UTC

Acquisities, Fusies, Overnames

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mei 2025, 20:50 UTC

Winsten

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mei 2025, 23:48 UTC

Acquisities, Fusies, Overnames

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mei 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mei 2025, 23:39 UTC

Marktinformatie

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mei 2025, 23:08 UTC

Marktinformatie

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mei 2025, 22:46 UTC

Acquisities, Fusies, Overnames

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mei 2025, 22:45 UTC

Acquisities, Fusies, Overnames

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mei 2025, 22:44 UTC

Top Nieuws

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 mei 2025, 22:20 UTC

Top Nieuws

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q EPS 10c >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q Sales $972M >JHX

20 mei 2025, 20:52 UTC

Top Nieuws

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mei 2025, 20:52 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2025, 20:52 UTC

Marktinformatie

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mei 2025, 20:30 UTC

Acquisities, Fusies, Overnames

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mei 2025, 20:28 UTC

Acquisities, Fusies, Overnames

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mei 2025, 20:23 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mei 2025, 20:22 UTC

Winsten

XP 1Q Adj EPS BRL2.29 >XP

20 mei 2025, 20:22 UTC

Winsten

XP 1Q Rev BRL4.345B >XP

20 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mei 2025, 20:20 UTC

Top Nieuws

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mei 2025, 20:19 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mei 2025, 20:11 UTC

Top Nieuws

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mei 2025, 20:09 UTC

Winsten

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Peer Vergelijking

Prijswijziging

REVOLUTION Medicines Inc Prognose

Koersdoel

By TipRanks

75.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 70.09 USD  75.53%

Hoogste 80 USD

Laagste 57 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor REVOLUTION Medicines Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Technische score

By Trading Central

40.67 / 41.96Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

176 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.